Home » UPC decisions » Central Division » CD Munich, 20 September 2023, order rejecting Rule 262.1(b) RoP request, UPC_CFI_1/2023

CD Munich, 20 September 2023, order rejecting Rule 262.1(b) RoP request, UPC_CFI_1/2023

2 min Reading time




Key takeaways

A request according to Rule 262.1(b) RoP for access to written pleadings and evidence by a member of the public requires a concrete, verifiable and legally relevant reason. The wish of a natural person to form an opinion on the validity of a patent out of a personal and a professional interest is not a legitimate reason as required by Rule 262.1(b) RoP. The reasons to be provided in the request must pertain to the reason(s) for access to the requested information per se. This applies regardless of whether there is confidential information contained in the written pleadings and evidence.

Division

Central Division (Section Munich)

UPC number

UPC_CFI_1/2023

Type of proceedings

Revocation action, Rule 262.1(b) RoP request

Parties

Relevant proceeding parties of main proceedings (revocation action):

Claimants:
Sanofi-Aventis Deutschland GmbH, Brüningstrasse 50, 65926 Frankfurt, Germany
Sanofi-Aventis Groupe, 82 Avenue Raspail, 94250 Gentilly, France
Sanofi Winthrop Industrie S.A., 82 Avenue Raspail, 94250 Gentilly, France

Defendant:
Amgen, Inc., One Amgen Center Drive, CA 91320-1799 Thousand Oaks, US

Patent(s)

EP 3 666 797

Jurisdictions

Body of legislation / Rules

Rule 262 RoP


Was the article helpful?


Categories


Tags

  • Martin Drews

    Attorney-at-law (Rechtsanwalt), UPC Representative, Counsel

Stay in the loop

Never miss a beat by subscribing to the email newsletter. Please see our Privacy Policy.

* = Required field